TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN

J. C. Gallagher; B. E.C. Nordin

doi:10.1016/S0140-6736(72)90173-0

TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN

J. C. Gallagher, B. E.C. Nordin

Research output: Contribution to journal › Article

80 Scopus citations

Abstract

Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.

Original language	English (US)
Pages (from-to)	503-507
Number of pages	5
Journal	The Lancet
Volume	299
Issue number	7749
DOIs	https://doi.org/10.1016/S0140-6736(72)90173-0
State	Published - Mar 4 1972
Externally published	Yes

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.1016/S0140-6736(72)90173-0

Fingerprint Dive into the research topics of 'TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN'. Together they form a unique fingerprint.

Cite this

Gallagher, J. C., & Nordin, B. E. C. (1972). TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN. The Lancet, 299(7749), 503-507. https://doi.org/10.1016/S0140-6736(72)90173-0

@article{e6ddf206feb843c78119c1ab9b7739c6,

title = "TREATMENT WITH {\OE}STROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN",

abstract = "Ethinyl{\oe}stradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. {\OE}strogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.",

author = "Gallagher, {J. C.} and Nordin, {B. E.C.}",

year = "1972",

month = mar,

day = "4",

doi = "10.1016/S0140-6736(72)90173-0",

language = "English (US)",

volume = "299",

pages = "503--507",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "7749",

}

TY - JOUR

T1 - TREATMENT WITH ŒSTROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN

AU - Gallagher, J. C.

AU - Nordin, B. E.C.

PY - 1972/3/4

Y1 - 1972/3/4

N2 - Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.

AB - Ethinylœstradiol was administered to 10 post-menopausal hyperparathyroid patients. There was a gradual fall in the fasting plasma-calcium and urine-calcium and in the 24-hour- urine calcium and hydroxyproline, which was maintained up to one year in the patients who continued therapy. Œstrogen treatment of hyperparathyroidism in post-menopausal women might be expected to prevent bone disease by inhibiting bone resorption, and stone disease by reducing urine-calcium.

UR - http://www.scopus.com/inward/record.url?scp=0015493551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015493551&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(72)90173-0

DO - 10.1016/S0140-6736(72)90173-0

M3 - Article

C2 - 4110019

AN - SCOPUS:0015493551

VL - 299

SP - 503

EP - 507

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7749

ER -